FDA approves Givlaari, first treatment for acute hepatic porphyria

The FDA approved Givlaari for the treatment of adults with acute hepatic porphyria, a rare genetic disorder that leads to buildup of toxic porphyrin molecules that form during the production of heme.“This buildup can cause acute attacks, known as porphyria attacks, which can lead to severe pain and paralysis, respiratory failure, seizures and mental status…

Weight parameters impact mortality in colorectal cancer

SAN ANTONIO — Obesity and underweight were associated with worse colorectal cancer outcomes, recurrence and mortality, compared with normal weight, according to results of a meta-analysis presented at the American College of Gastroenterology Annual Meeting.“Obesity is thought to play a role in the underlying pathogenesis of colorectal cancer, but this mechanism is not fully understood,”…

Dicerna, Novo Nordisk partner to develop novel liver disease therapies

Dicerna Pharmaceuticals and Novo Nordisk announced an agreement to develop RNA interference therapies for liver-related cardiometabolic diseases, according to a press release.“We are excited to collaborate with Novo Nordisk on this broad research and development effort that extends the reach of our GalXC platform to a wide range of liver cell targets and maximizes our…

Multidisciplinary program reduces GI complications after orthopedic surgery

SAN ANTONIO — Implementing a multidisciplinary improvement program helped reduce bowel complications among patients recovering from orthopedic surgery, according to study results presented at the American College of Gastroenterology Annual Meeting.Melissa Latorre, MD, MS, from NYU Langone Health, said GI complications in patients who undergo orthopedic surgery are common but underreported. Among the most common…